Kyverna Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance
Kyverna Therapeutics, Inc. (KYTX) had Deferred Tax Assets, Valuation Allowance of $91.42 million as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-03-26
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $91.42M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $65.59M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $31.77M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2025-12-31 | $91.42M 10-K · filed 2026-03-26 |
| 2024-12-31 | $65.59M 10-K · filed 2026-03-26 |
| 2023-12-31 | $31.77M 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |